-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2024-516504-42-00
5
2022-03-05
Respiratory distress syndrome in preterm infants
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-504653-12-00
4
2020-02-10
Patients with previously untreated Richter Transformation or patients
-
2024-518811-20-00
4
2025-09-30
Early-Stage, PIK3CA-Mutated Breast Cancer (BC)
-
2022-503001-38-01
5
2025-07-08
HR-positive HER-2- negative Breast Cancer
-
2024-516212-24-00
4
2024-10-08
Chronic Myeloid Leukemia
-
2022-500571-32-00
4
2024-05-15
Early-Stage Unfavorable Classical Hodgkin Lymphoma
-
2024-514458-61-01
4
2024-02-05
HER2+ early breast cancer
-
2022-502322-41-00
5
2023-09-12
Metastatic breast cancer
-
2022-502634-52-00
5
2023-05-16
prostate cancer
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2023-505210-18-00
5
2021-12-17
Early stage HER2-positive breast cancer (T stage >= T3, lymph node pos
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2024-511929-60-00
4
2021-01-28
Waldenström’s Macroglobulinemia
-
2023-505042-25-00
5
2020-05-05
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer